Purchase this article with an account.
Martine J. Jager; Uveal consequences of CTLA-4 and PD-1 inhibition. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4409. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Immune checkpoint inhibitors are being used to treat many different types of malignancies, and help patients live longer. As the working mechanism of these inhibitors is de-blocking T cells, this treatment leads to more activity of T cells in general. This leads to many general and ocular side effects.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only